drugset / Trial / NCT01876719

AR08 for Treatment of ADHD in Children

NCT01876719 ↗

Phase 2 Completed 122 enrolled Arbor Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio. One-hundred twenty (120) patients are planned to be randomized. Each patient will receive AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.

Timeline

Start
2013-06
Primary completion
2014-10
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AR08 Unknown 0.5 mg —
Subject AR08 Unknown 1 mg —
Subject AR08 Unknown 2 mg —